All In MedTech

Device Trial Radar · NCT03872115

Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease

Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease - Phase 1

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 18, 2019

Primary completion

Apr 2020

Study completion Apr 2020

Sponsor

Lead sponsor
Virginia Commonwealth UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Michael J. Fox Foundation for Parkinson's Research
First posted
Mar 13, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to determine optimum dose of vibration delivered by an experimental device called PDVibe2 required to treat freezing of gait in persons with Parkinson's disease (PD). The PDVibe2 was developed by Resonate Forward, LLC (RF). This PDVibe2 was designed to administer vibration therapy to the wearer to improve gait and balance in persons with PD while wearing the device.

Conditions

  • Parkinson Disease

Interventions

  • PDVibe2Device

    The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Functional Ambulation Profile (FAP) ScoreTime frame: Throughout study completion, from 9 to 34 days.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.